Sylentis, S.A. clinical trials
A subsidiary of PharmaMar
The registry lists 12 studies whose lead sponsor is Sylentis, S.A.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2026.
Status
- Completed
- 12
Registry sponsor names on this page
- Sylentis, S.A.12 studies
Something wrong with this grouping? Tell us on the PharmaMar page.
Studies
Recruiting first, then most recently updated. Showing 12 of 12. All PharmaMar studies →
- Safety Study of Tivanisiran to Treat Dry EyeCompletedNCT05310422Phase 3
Sponsor listed in the registry: Sylentis, S.A.
- A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT05637255Phase 2
Sponsor listed in the registry: Sylentis, S.A.
- Tivanisiran for Dry Eye in Subjects With Sjögren's SyndromeCompletedNCT04819269Phase 3
Sponsor listed in the registry: Sylentis, S.A.
- Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye DropsCompletedNCT04782271Phase 1
Sponsor listed in the registry: Sylentis, S.A.
- SYL040012, Treatment for Open Angle GlaucomaCompletedNCT02250612Phase 2
Sponsor listed in the registry: Sylentis, S.A.
- HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)CompletedNCT03108664Phase 3
Sponsor listed in the registry: Sylentis, S.A.
- Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular PainCompletedNCT02455999Phase 2
Sponsor listed in the registry: Sylentis, S.A.
- Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular PainCompletedNCT01776658Phase 1/2
Sponsor listed in the registry: Sylentis, S.A.
- Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle GlaucomaCompletedNCT01739244Phase 2
Sponsor listed in the registry: Sylentis, S.A.
- SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm HgCompletedNCT01227291Phase 1/2
Sponsor listed in the registry: Sylentis, S.A.
- Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy VolunteersCompletedNCT01438281Phase 1
Sponsor listed in the registry: Sylentis, S.A.
- Tolerance and Effect on Intraocular Pressure After Administration of SYL040012CompletedNCT00990743Phase 1
Sponsor listed in the registry: Sylentis, S.A.